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In response to microenvironmental signals, innate recogni-tion of tissue damage or pathogen exposure, and signalsfrom activated lymphocyte subsets, macrophages undergo
adaptive responses essential for a coordinated immune
response, resistance to pathogens, and tissue repair. During
the last few years increasing evidence has accumulated indi-
cating that macrophage plasticity can be viewed as a spec-
trum of activation status between the classic pro-inflammato-
ry (M1) program, induced by bacterial moieties such as
lipopolysaccharides and the Th1 cytokine interferon-γ, and
the alternative tissue repair-prone (M2) program, originally
discovered as a response to the Th2 cytokine interleukin-4,
mirroring Th1/Th2 polarization.1 It is now appreciated that
M2-like functional phenotypes can also be induced by other
signals, including antibody immune complexes together with
lipopolysaccharides/interleukin-1, glucocorticoids, transform-
ing growth factor beta-β, and interleukin-10.2
Polarized macrophages differ greatly in expression of
immunoregulatory genes and profoundly influence immune
responses and tissue homeostasis.3,4 M1 macrophages are
characterized by high levels of pro-inflammatory cytokines
(interleukin-12, interleukin-23, tumor necrosis factor-α) and
an interleukin-12high/interleukin-10low phenotype, produce
reactive nitrogen and oxygen intermediates, express high lev-
els of major histocompatibility class II and co-stimulatory
molecules, and display microbicidal activity. In this context, it
is relevant to recall that M1 macrophages are also character-
ized by marked iron sequestration properties, which con-
tribute to the cells’ bacteriostatic effects.5 M1 macrophages
are part of polarized Th1 responses and mediate resistance to
intracellular pathogens and tumors. Of note, under these acti-
vated conditions, M1 cells can also elicit tissue disruptive
reactions. Conversely, M2 macrophages show increased
phagocytic activity, high expression of scavenging, mannose
and galactose receptors, production of ornithine and
polyamines through the arginase pathway, and an inter-
leukin-12low/interleukin-10high phenotype. In general, these
cells participate in polarized Th2 responses, help in parasite
clearance, dampen inflammation, promote tissue remodeling,
and possess immunoregulatory functions.6 Macrophages are
also key elements linking inflammation and cancer, and
tumor-associated macrophages are also characterized by an
alternative-like activation phenotype.7,8
In addition to their role in immunity, macrophages are of
central importance to body iron homeostasis, as the main iron
supply for erythropoiesis derives from the iron recycled by
macrophages after phagocytosis of senescent red blood cells.9
Iron retention in the reticuloendothelial system is a well char-
acterized response of body iron homeostasis to inflammation,
as a host’s attempt to withhold iron from the invading
pathogens. This may eventually restrict iron availability for
erythroid precursors and may contribute toward causing the
common condition of inflammation-related anemia.
However, recent studies have revealed that the role of
macrophages in iron homeostasis is multifaceted and more
complex than previously suspected.
In this issue of Haematologica, Corna and colleagues show
that mouse macrophage polarization also affects iron home-
ostasis.10 Similar results were reported earlier this year for
human polarized macrophages,11 indicating that differential
iron management is a conserved functional property of
human and murine polarized macrophages, differently from
other functional aspects not conserved across species.3
Moreover, a recent study showed that glucocorticoids polar-
ize monocytes toward a M2 phenotype characterized by
hemoglobin clearance and export of heme-derived iron.12
In their study, Corna and colleagues found that M2 cells
have lower levels of H ferritin (Ft), the iron storage protein,
and higher expression of membrane proteins involved in iron
uptake, such as the transferrin receptor (TfR1) and the CD163
hemoglobin/haptoglobin receptor. Moreover, the high
expression of ferroportin (Fpn), the only known iron exporter
from cells, resulted in elevated iron release activity by M2
cells. In line with the expression of Ft and TfR1, the binding
activity of the iron regulatory proteins (IRP), which post-tran-
scriptionally regulate the expression of a number of iron
genes,13 was lower in M1 than in M2 cells. Since IRP-binding
activity and the labile iron pool are usually inversely related,14
this result apparently contrasts with the larger labile iron pool
(measured by the calcein method) found in M2 cells.
Interestingly, high Fpn mRNA levels counteracted the
impaired translation of Fpn mRNA due to increased IRP-bind-
ing activity. This finding is in line with the results of a recent
study which showed that the selective inactivation of IRP2 in
mouse macrophages had no consequences on Fpn-mediated
iron handling by macrophages, and thus put into question the
role of IRP-mediated control of Fpn expression.15 Overall, the
analysis of M1 macrophages confirmed that pro-inflammato-
ry stimuli trigger changes in gene expression (such as Fpn
repression and Ft induction) favoring iron sequestration.5,16
Conversely, it appears that M2 macrophages are character-
ized by an iron release-prone phenotype, and thus there are
large differences in both intra- and extracellular iron availabil-
ity between the two populations.
Iron sequestration in M1 macrophages operates as a bacte-
riostatic mechanism. The functional implications of the iron
export activity of M2 macrophages are, in contrast, still unde-
fined. Considering the evidence that M2 macrophages partic-
ipate in the regeneration of acutely injured mouse skeletal
muscle,17 Corna and colleagues suggested that iron release
from M2 macrophages could play a relevant role in muscle
repair. Recently, Recalcati and colleagues11 reported that con-
ditioned medium of M2 macrophages sustained faster growth
of malignant and non-malignant cell lines, and because iron is
an essential cofactor for DNA synthesis they suggested
that tumor-associated macrophages could provide iron to
the microenvironment to sustain the high requirements of
tumor cells. Fpn appears to play a key role in this process
because the conditioned medium of M2 macrophages
derived from a patient with loss of function Fpn mutation
did not show the cell growth accelerating effect. The pres-
ence of functional Fpn on the plasma membrane appears
to be a key determinant of iron release not only by
macrophages but also by tumor cells. Interestingly,
reduced Fpn expression (and hence higher iron content)
has recently been found in breast cancer cells compared to
in non-malignant breast epithelial cells.18 Notably, in this
extensive study it was also shown that Fpn levels in
human tumors were inversely correlated with malignant
potential and clinical outcome in large cohorts of breast
cancer patients. Altogether, these studies highlight the
importance of the Fpn-mediated control of iron availabili-
ty in the tumor microenvironment.
It is now increasingly appreciated that beyond their long
recognized role in promoting inflammation, macrophages
undergo alternative activation producing phenotypes with
completely different and in some cases opposite biological
properties. Their role in tissue homeostasis and in a vari-
ety of pathological conditions, ranging from infectious dis-
eases to tumors, has been recognized, and activating sig-
nals, surface markers, and molecular pathways associated
with different forms of macrophage activation have been
progressively characterized. Inspired by the intellectual
framework of lymphocyte polarized activation during
adaptive immune responses, our understanding of
macrophage polarization has been dominated by
immunological phenotypes and biological implications.
Beyond the immunological phenotypes, the data from
Corna and colleagues10 and others11,12 now focus our atten-
tion on the relevance of the macrophage metabolic profile
during activation of these cells. In particular, iron manage-
ment emerges as a metabolic signature of macrophage
activation, with M1 cells committed to reduce iron avail-
ability to the microenvironment via a Fthigh/Fpnlow pheno-
type and M2 to increase iron availability to tissues via
their Ftlow/Fpnhigh phenotype.
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Figure 1. Schematic representa-
tion of iron uptake and export in
polarized macrophages. M1
macrophages are characterized
by the coordinated regulation of
genes related to iron metabolism
(ferritinhigh/ferroportinlow) which
results in iron retention. This is of
relevance for their bacteriostatic
properties but also represents the
cellular basis for the anemia of
chronic disease. Conversely, M2
macrophages are characterized
by high levels of scavenger recep-
tors (CD163) which enable effi-
cient iron uptake, and a ferritin-
low/ferroportinhigh phenotype that
supports iron donation to the
microenvironment. This may con-
tribute to tissue repair by provid-
ing iron to proliferating parenchy-
mal cells and to fibroblasts for
collagen synthesis, but also sus-
tain tumor growth in the case of
tumor-associated macrophages.
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Erythropoietin (EPO) regulates red blood cell produc-tion by binding to its cell surface receptor, EPO-R,expressed on erythroid progenitor cells. Although
EPO was originally believed to be an erythroid-specific
hematopoietic cytokine, for over a decade, a substantial
body of scientific evidence has accumulated to demon-
strate that the biological effects of EPO are not limited to
the erythron (Figure 1). In this issue of the journal, Lifshitz
and colleagues1 report on their most recent contribution to
this field of research by demonstrating that, within the
hematopoietic system, EPO may exhibit modulatory
effects on macrophage number and function. The authors
examined in vivo effects of EPO on splenic macrophages
and inflammatory peritoneal macrophages, as well as in
vitro effects of EPO on bone marrow-derived macrophages
in culture. The experimental data show that splenic
macrophage numbers were increased in mice in response
to systemic EPO treatment. In transgenic mice engineered
to constitutively over-express endogenous EPO, an even
more significant increase in the number of splenic
macrophages was observed, possibly as part of an adap-
tive mechanism leading to increased erythro-phagocytosis
in severely polycythemic mice.2 Inflammatory
macrophages isolated from murine peritoneum displayed
enhanced activation and phagocytic function, both fol-
lowing exogenous EPO treatment and in association with
the over-expression of endogenous EPO, but without an
increase in the number of macrophages migrating into the
peritoneal cavity. The in vivo activity of EPO observed in
these studies may be associated with direct effects on
macrophages, indirect effects of EPO on other cell types
that modulate macrophage number and function, or a
combination of direct and indirect effects. Additional
experiments by the investigators using cultured murine
primary bone marrow-derived macrophages revealed
enhanced activation and phagocytic function of the cells
following EPO treatment. These direct EPO effects were
associated with increased macrophage nitric oxide and
interleukin (IL)-12 secretion, whereas IL-10 production
was decreased, consistent with the generation of a pro-
inflammatory phenotype and classical Th1 immune
response.
The investigation of non-erythroid biological effects of
EPO raises the question of the role of the erythroid recep-
tor EPO-R, which is ubiquitously expressed at relatively
low levels in many non-hematopoietic tissues. Lifshitz
and colleagues addressed this issue in part by demonstrat-
ing that the newly discovered effects of EPO on
macrophages were associated with the expression of
EPO-R mRNA in cultured murine bone marrow-derived
macrophages. The investigators further demonstrated the
ability of EPO to mediate the increased phosphorylation
of STAT proteins, as well as the induction of AKT and
ERK2 phosphorylation and the nuclear translocation of
p65 NFκB in macrophages. Although the direct effects of
EPO on intracellular signal transduction and the induced
changes in macrophage phenotype and function are pre-
sumably mediated in part by EPO-R, further studies will
be necessary to delineate the structure of the cell surface
receptor that mediates the effects of EPO in macrophages.
Previous studies investigating non-erythropoietic EPO
activities suggested that, in some experimental models,
the tissue protective activity of EPO and of some EPO
derivatives without erythropoietic activity may be medi-
ated by a heteroreceptor complex between EPO-R and the
common β receptor (βC-R) – a signal-transducing compo-
nent of the cellular receptors for granulocyte-macrophage
colony-stimulating factor, IL-3 and IL-5.3,4 Other studies
reported, however, that the βC-R may not be required for
EPO-induced signal transduction and its cellular effects in
some non-hematopoietic cells.5,6 The detection of low lev-
els of cell surface EPO-R on non-hematopoietic cells has
been made possible by using a novel radiolabeled-EPO
binding assay to demonstrate as few as 50 EPO binding
